Chinese PLA General Hospital: Lymphoma, Non-Hodgkin trials

The registry lists 16 Lymphoma, Non-Hodgkin studies with Chinese PLA General Hospital as lead sponsor. 10 are open to participants now and 0 have results posted.

Phase 1 15Phase 2 13No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• BEX101 in B-cell Non-Hodgkin's LymphomaRecruitingNCT07882641Phase 1/2
• Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMARecruitingNCT07620314Phase 1
• Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHLRecruitingNCT06321289Phase 1/2
• TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHLRecruitingNCT06014073Phase 1/2
• TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHLRecruitingNCT05631912Phase 1/2
• Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHLRecruitingNCT05554939Phase 1/2
• Chidamide Bridging for CAR-T TherapyRecruitingNCT05370547Phase 1/2
• Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid TumorsRecruitingNCT05320640Phase 1/2
• Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen ReceptorRecruitingNCT04337606Phase 1/2
• CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive LymphomasRecruitingNCT02259556Phase 1/2
• Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's LymphomaStatus unknownNCT04897477Phase 1/2
• Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin LymphomaStatus unknownNCT04012892Phase 1
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22Status unknownNCT03185494Phase 1/2
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20CompletedNCT03097770Phase 1/2
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19Status unknownNCT01864889Not applicable
• Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to ChemotherapyStatus unknownNCT01735604Phase 1/2